Granted Patent B2

US 12,458,589 · App. 17/250,042 · Granted Nov 4, 2025

Inventors: Karun D. Naga (Los Altos, CA); Hanson S. Gifford, III (Woodside, CA); Stephen W. Boyd (San Francisco, CA); Patrick H. Ruane (El Dorado Hills, CA); Jackie Joe Hancock (Berkeley, CA); Michael Feldstein (San Francisco, CA); Koon Kiat Teu (Singapore, SG); Honglei Wang (Singapore, SG); Jingnan Luo (Singapore, SG); Daniel Boon Lim Seet (Singapore, SG); Wei Li Lee (Singapore, SG); Nassireddin Mokarram-Dorri (Campbell, CA)

Assignee: Foundry Therapeutics, Inc.

A61K9/0024A61K9/7007A61K31/445A61K47/26A61K47/34A61P23/02

Abstract

Claims (38)

1 . A depot for treatment of postoperative pain via sustained, controlled release of an analgesic, comprising:

a therapeutic region comprising:

poly(lactide-co-glycolide) (PLGA),

at least 50 wt % bupivacaine, and

0.1 wt % to 6 wt % polysorbate 20,

wherein the therapeutic region includes a first surface, a second surface opposite the first surface, and an exposed lateral surface between the first and second surfaces, and

wherein the bupivacaine comprises a plurality of particles mixed with the PLGA;

a first control region covering the first surface of the therapeutic region, the first control region comprising PLGA;

a second control region covering the second surface of the therapeutic region, the second control region comprising PLGA; and

a plurality of pre-formed openings extending through the therapeutic region, the first control region, and the second control region,

wherein the first and second control regions each have a thickness that is less than 1/30 of a thickness of the therapeutic region, and the thickness of each of the first and second control regions is within a range from 5 μm to 50 μm,

wherein the depot has a total thickness within a range from 1 mm to 3 mm, and

wherein the depot is configured to be implanted at a treatment site in vivo and, while implanted, release the bupivacaine at the treatment site for no less than 7 days.

2 . The depot of claim 1 , wherein the bupivacaine comprises at least 50% of a total mass of the depot.

3 . The depot of claim 1 , wherein the plurality of pre-formed openings have substantially parallel trajectories.

4 . The depot of claim 1 , wherein the plurality of pre-formed openings comprise cylindrical holes.

5 . The depot of claim 1 , wherein, when the depot is implanted at the treatment site, at least some of the bupivacaine is released directly from the therapeutic region to the treatment site via the plurality of pre-formed openings.

6 . The depot of claim 1 , wherein the plurality of pre-formed openings extend through a thickness of the depot.

7 . The depot of claim 1 , wherein a ratio of the polysorbate to the PLGA to the bupivacaine in the therapeutic region is within a range from 0.1:10:20 to 2:10:20.

8 . The depot of claim 1 , wherein the depot has a triangular shape.

9 . The depot of claim 1 , wherein the depot is configured to release the bupivacaine at the treatment site for no less than 14 days.

10 . A depot for treatment of pain, the depot comprising:

a therapeutic region comprising at least 50 wt % bupivacaine and further comprising poly(lactide-co-glycolide) (PLGA), the therapeutic region having an upper surface, a lower surface opposite the first surface, and an exposed lateral surface between the upper and lower surfaces, wherein the bupivacaine comprises a plurality of particles mixed with the PLGA, and wherein the therapeutic region has a first thickness;

an upper control region covering the upper surface of the therapeutic region, the upper control region comprising PLGA, wherein the upper control region has a second thickness less than 1/30 of the first thickness, and the second thickness is within a range from 5 μm to 50 μm;

a lower control region covering the lower surface of the therapeutic region, the lower control region comprising PLGA, wherein the lower control region has the second thickness; and

a plurality of pre-formed openings extending through the upper control region, the therapeutic region, and the lower control region, wherein when the depot is implanted at the treatment site, at least some of the bupivacaine is released directly from the therapeutic region to the treatment site via the plurality of pre-formed openings,

wherein the depot has a total thickness of at least 1.5 mm, and

wherein the depot is configured to be implanted at a treatment site in vivo and, while implanted, release the bupivacaine at the treatment site for no less than 7 days.

11 . The depot of claim 10 , wherein the bupivacaine comprises at least 50% of a total mass of the depot.

12 . The depot of claim 10 , wherein the plurality of pre-formed openings have substantially parallel trajectories.

13 . The depot of claim 10 , wherein the plurality of pre-formed openings comprise cylindrical holes.

14 . The depot of claim 10 , wherein the depot has a triangular shape.

15 . The depot of claim 1 , wherein the first and second control regions are applied to the therapeutic region via dip coating.

16 . The depot of claim 1 , wherein a ratio of a surface area of the depot to a volume of the depot is at least 1.

17 . The depot of claim 1 , wherein the depot is configured to maintain structural integrity in vivo for at least 7 days.

18 . The depot of claim 1 , wherein the treatment site is an intracapsular space of a knee joint.

19 . The depot of claim 18 , wherein the treatment site is selected from the following: a suprapatellar pouch, a medial gutter, or a lateral gutter of the intracapsular space of the knee joint.

20 . The depot of claim 18 , wherein the depot is configured to maintain structural integrity for at least 7 days after being implanted in the intracapsular space of the knee joint.

Assignments (7)

Priority Claims (2)

Continuity (4)

References Cited (400)